Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay
18.9.2025 07:00:00 CEST | Business Wire | Press Release
Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface skin cells stop performing at the same level, or “go to sleep,” causing fine lines, dehydration, and looser skin, in turn leading to skin looking and feeling less firm and more fragile.1
Skin Activator technology serves as a “wake-up call” to sleeping surface skin cells. The unique complex is powered by encapsulated CICA to help restore the skin’s moisture barrier to visibly plump and firm skin as well as microdosed mandelic acid to increase surface skin cell turnover to visibly reduce dull, uneven skin. In clinical trials, the Skin Activator Hydrating & Firming Lotion showed to be effective in improving the appearance of skin crepiness and smooth skin’s texture in one week. It was also proven to hydrate for firmer-looking skin in just four weeks. Moreover, when patients were asked about their experiences, 88% of Skin Activator Hydrating & Firming Cream users said their skin looked less crepey in 2 days, and 87% said their skin appeared more youthful after one week.2
“This launch signals a turning point in how we approach skin longevity. It’s more fundamental than wrinkles or loss of firmness, it’s about preserving surface skin health at the cellular level. As skin undergoes changes with age, it demands more precise, science-driven support. This insight fueled the development of our Skin Activator Hydrating & Firming line: a dermatologist-developed routine designed to strengthen, revitalize, and transform skin’s appearance.” ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS
|
In developing the Skin Activator Hydrating & Firming Line, Galderma partnered with a medical advisory board of leading dermatologists.
“As a dermatologist, I’m always looking for what’s next in skin science, especially when it comes to aging. That’s why I was so excited to work with Cetaphil on the Skin Activator Hydrating & Firming line. We took on one of the biggest underlying causes of visible aging: surface skin health and cell senescence. By targeting these ‘zombie cells,’ we’re helping to support skin renewal in a way that’s truly backed by science. It’s been incredibly rewarding to help bring that kind of innovation to a skincare routine patients can use all over, every day.” DR. GLYNIS ABLON*
|
A new era of skin activation, backed by science and brought to life by a cultural icon
To help bring this segment-defining line to life, Cetaphil is proud to partner with acclaimed actress, director, and advocate, Mariska Hargitay. Known for her strength, compassion, and authenticity, Hargitay represents a powerful voice in embracing beauty at every stage of life. As the face of the campaign, she will help share a message of empowerment and reinvention – giving women the tools to reawaken both their skin’s look and their aspirations. Hargitay’s partnership will span across a robust marketing effort, inclusive of PR, advertising, in-store, retailer e-commerce, and social.
Fragrance-free, non-comedogenic, and hypoallergenic, the Skin Activator Hydrating & Firming line also embraces the trending notion of “skinification,” or using facial care-inspired ingredients to address full-body skincare needs. Products within the newly launched Skin Activator Hydrating & Firming Line include:
- Cetaphil Hydrating & Firming Cream for Neck, Chest, and Face (3.4 oz.)
- Cetaphil Hydrating & Firming Cream for Body (12 oz.)
- Cetaphil Hydrating & Firming Lotion (16 oz.)
The Hydrating & Firming Line is now widely available for purchase in the United States. Galderma is working to bring this new innovation to other international markets where Cetaphil is already available. See full list of retailers here: https://www.cetaphil.com/us/where-buy. For more information, consumers can also follow Cetaphil on Instagram (@Cetaphil) and TikTok (@Cetaphil) or visit www.cetaphil.com.
About Cetaphil®
Over seventy-five years ago, a leading pharmacist created the first Cetaphil product – a gentle, yet powerful formula that would clean without stripping and moisturize without clogging. Today, Cetaphil is a dermatologist recommended sensitive skincare brand and is recognized around the world. With the help of leading global skincare experts, they continue to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain skin's health every day. For more information, visit www.cetaphil.com.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermato-logical Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References and disclaimers:
- Novel Strategy for Strengthening Dermatoporotic Skin by Managing Cellular Senescence. J Drugs Dermatol. 2024 Sep 1;23(9):748-756. doi: 10.36849/JDD.8388.
- Galderma 12-week in-use study-consumer data questionnaire. Subject data on file.
* Paid Galderma Consultant; Galderma Clinical Study investigator for the Cetaphil hydrating & firming product line
View source version on businesswire.com: https://www.businesswire.com/news/home/20250917102132/en/
Contacts
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Jeffrey Smith
Head of U.S. Communications
jeffrey.smith@galderma.com
+ 1 (682) 401-8428
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom